Evidence map›Paper›PMID 23020264›Full record

Trial reportBMC neurology2012

Effectiveness of intravenous dexamethasone versus propofol for pain relief in the migraine headache: a prospective double blind randomized clinical trial.

Hassan Soleimanpour, Rouzbeh Rajaei Ghafouri, Aliakbar Taheraghdam, Dawood Aghamohammadi, Sohrab Negargar, Samad E J Golzari, Mohsen Abbasnezhad

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in BMC neurology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Intravenous Migraine Treatment in Children and Adolescents.Current pain and headache reports · 2020
    Review
  12. Review
  13. Review
  14. Observational
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Hassan SoleimanpourEmergency Medicine Department, Tabriz University of Medical Sciences, Daneshgah Street, Tabriz 51664, I,R, IRAN. soleimanpourh@tbzmed.ac.ir
Rouzbeh Rajaei Ghafouri
Aliakbar Taheraghdam
Dawood Aghamohammadi
Sohrab Negargar
Samad E J Golzari
Mohsen Abbasnezhad
Tabriz University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are many drugs recommended for pain relief in patients with migraine headache.

methodsIn a prospective double blind randomized clinical trial, 90 patients (age ≥ 18) presenting to Emergency medicine Department with Migraine headache were enrolled in two equal groups. We used intravenous propofol (10 mg every 5-10 minutes to a maximum of 80 mg, slowly) and intravenous dexamethasone (0.15 mg/kg to a maximum of 16 mg, slowly), in group I and II, respectively. Pain explained by patients, based on VAS (Visual Analogue Scale) was recorded at the time of entrance to ED, and after injection. Data were analyzed by paired samples t test, using SPSS 16. P < 0.05 was considered to be statistically significant.

resultsThe mean of reported pain (VAS) was 8 ± 1.52 in propofol group and 8.11 ± 1.31 in dexamethasone group at presenting time (P > 0.05). The VAS in propofol group was obviously decreased to 3.08 ± 1.7, 1.87 ± 1.28 and 1.44 ± 1.63 after 10, 20 and 30 minutes of drug injection, respectively. The VAS in dexamethasone group was 5.13 ± 1.47, 3.73 ± 1.81 and 3.06 ± 2 after 10, 20 and 30 minutes of drug injection, respectively. The mean of reported VAS in propofol group was less than dexamethasone group at the above mentioned times (P < 0.05). The reduction of headache in propofol group, also, was very faster than dexamethasone group (P < 0.05). There were no adverse side effects due to administration of both drugs.

conclusionsIntravenous propofol is an efficacious and safe treatment for patients presenting with Migraine headache to the emergency department.

trial registrationClinical Trials IRCT201008122496N4.

Indexed as

AdultAnesthetics, IntravenousAnti-Inflammatory AgentsDexamethasoneDouble-Blind MethodFemaleHeadacheHumansInjections, IntravenousMaleMigraine DisordersPain MeasurementPropofolProspective StudiesTreatment OutcomeAnesthetics, IntravenousAnti-Inflammatory AgentsDexamethasonePropofol

Identifiers

PMID23020264
PMCPMC3522017
OpenAlexW1965660595

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.